Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
Title:
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
Author:
Guérin, O. Formento, P. Lo Nigro, C. Hofman, P. Fischel, J. L. Etienne-Grimaldi, M. C. Merlano, M. Ferrero, J. M. Milano, G.